SRPT241220C230000
- 0.05
- 0.000.00%
Sarepta Therapeutics Newsroom
25 U.S. 'Highest Conviction' Stocks – UBS
A Glimpse Into The Expert Outlook On Sarepta Therapeutics Through 15 Analysts
Express News | HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $75 Price Target
Express News | Sarepta Therapeutics Inc - Anticipates Filing for Accelerated Approval of Srp-9003 in 2025
Express News | Sarepta Therapeutics Completes Enrollment in Emergene, a Phase 3 Clinical Study of Srp-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
Sarepta Therapeutics Insider Sold Shares Worth $1,310,820, According to a Recent SEC Filing
Insider Sale: Director at $SRPT (SRPT) Sells 10,500 Shares
Wolfe's Top 12 Shorted Stocks: FSLR, BE, WBA, and More
PepGen Stock Craters 35% on FDA Clinical Hold
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst
FDA's New Accelerated Approval Guidance to Benefit Rare Disease Drug Development, Analysts Believe | NASDAQ:SRPT
Wall Street Analysts See a 47.95% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High?
Antisense & RNAi Therapeutics Market Report 2024, Featuring Profiles of Alnylam Pharmaceuticals, Arbutus Biopharma, Benitec Biopharma, GSK, Ionis Pharmaceuticals, Sanofi, Sarepta Therapeutics & More - ResearchAndMarkets.com
Based On Its ROE, Is Sarepta Therapeutics, Inc. (NASDAQ:SRPT) A High Quality Stock?
Why Is Sarepta Therapeutics (SRPT) Up 4.9% Since Last Earnings Report?
Sarepta Therapeutics Is Maintained at Sell by HC Wainwright & Co.
Sarepta Therapeutics Analyst Ratings
H.C. Wainwright Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Cuts Target Price to $75